Matthew Dennis

Merck & Co. has chosen a preclinical asset from Chinese biotech Hansoh Pharma for its shot at developing an oral small molecule GLP-1 receptor agonist.

Novo Nordisk on Wednesday announced that it completed the $11-billion purchase of three manufacturing sites from its parent Novo Holding, after the former finalised its $16.5-billion acquisition of Catalent.

Hospitals in China are turning away from AstraZeneca's medicines, threatening the company's position as the country's leading foreign drugmaker by sales, the Financial Times reported Wednesday.

Novartis entered into a multi-year research collaboration with BioAge Labs in an effort to discover novel targets for therapies that address age-related diseases and conditions.

Bristol Myers Squibb is adding a pair of experimental amyloid-beta targeting antibodies to its pipeline via a deal with BioArctic potentially worth over $1.3 billion.

Astellas is betting on Sangamo Therapeutics' neurotropic adeno-associated virus (AAV) capsid, STAC-BBB, to effectively deliver its intravenously

Having only completed the purchase of MorphSys earlier in the year, Novartis is now reported to be shuttering the unit, with the decision affecting 330 jobs.

With an FDA decision due in a little over a month on its non-opioid drug suzetrigine in acute pain, Vertex Pharmaceuticals on Thursday unveiled

Shares in Novo Nordisk plunged as much as 26% in pre-market trading on Friday as investors reacted to Phase III data for the company's next obesity hopeful CagriSema.

After a four-month delay, Humacyte has gained FDA approval of Symvess (acellular tissue engineered vessel-tyod) for use in arterial replacement and repair.